Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 1;46(4):183-184.
doi: 10.1097/COC.0000000000000984. Epub 2023 Mar 24.

Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors

Matthew J Hadfield  1 , Hetal Mistry  1 , Ari Pelcovits  1 , Rani Bansal  2 , Sarah Andrea  3 , Adel Chergui  1 , Kristy Ramphal  1 , Matthew Austin  4 , Humera Khurshid  1
Affiliations

Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors

Matthew J Hadfield et al. Am J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168.
    1. Smithy JW, Faleck DM, Postow MA. Facts and hopes in prediction, diagnosis, and treatment of immune-related adverse events. Clin Cancer Res. 2022;28:1250–1257.
    1. Johnson DB, Jakubovic BD, Sibaud V, et al. Balancing cancer immunotherapy efficacy and toxicity. J Allergy Clin Immunol Pract. 2020;8:2898–2906.
    1. Kartolo A, Sattar J, Sahai V, et al. Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol. 2018;25:e403–e410.
    1. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.

MeSH terms

Substances